CytomX nets $93.4M in underwritten common stock offering; 76.9M shares at $1.30

CytomX Therapeutics, Inc.

Sold 76,923,076 shares of common stock at $1.30/share, generating ~$93.4M in net proceeds after underwriting discounts and expenses.
Proceeds to be used for research and development, general corporate purposes, and working capital.
Underwriting syndicate led by Jefferies and Piper Sandler & Co.
Offering closed on May 13, 2025; shares issued under effective shelf registration statement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.